Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice

Cynthia Soon, Peter Crouch, Bradley Turner, Catriona Ann McLean, Katrina Laughton, Julie Atkin, Colin Masters, Anthony White, Qiao-Xin Li

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)


Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neurodegenerative disorder characterized by progressive deterioration of motor neurons in the spinal cord, brainstem, and cerebral cortex. Matrix metalloproteinase-9 (MMP-9) is proposed to be a biomarker for ALS due to a potential pathological role in the disease. However, despite numerous studies, it is still unclear whether there is a direct correlation between MMP-9 expression in serum and progression of disease. Therefore, we used a TgSOD1G93A mouse with a low transgene copy number. This model shows slow disease progression analogous to human ALS and provides a useful model to study biomarker expression at different stages of disease.
Original languageEnglish
Pages (from-to)260 - 266
Number of pages7
JournalNeuromuscular Disorders
Publication statusPublished - 2010

Cite this